High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: Implications for personalized drug safety

Personalized Medicine

Volumn 3, Issue 2, 2006, Pages 131-137

  Ruaño, Gualberto ^a   Makowski, Greg ^b   Windemuth, Andreas ^a   Kocheria, Mohan ^a   Weiss, Stephen ^c   Goethe, John W ^b   Bower, Bruce ^a   Wu, Alan H B ^d   Thompson, Paul D ^b  

^a Genomas Inc   (United States)

^b HARTFORD HOSPITAL   (United States)

^c Tm Bioscience Corporation   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reactions; Alleles; CYP2C19; CYP2C9; CYP2D6; DNA typing; Drug metabolism; Patient safety

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DRUG; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA FINGERPRINTING; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG UTILIZATION; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

EID: 33646812979     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/17410541.3.2.131     Document Type: Article

References (20)

1. Lazarou J, Pomeranz B, Corey P: Incidence of adverse drug reactions in hospitalized patients. JAMA 279, 1200-1205 (1998).
2. Lewis DFV: 57 Varieties: The human cytochromes P450. Pharmacogenomics 5, 305-318 (2004).
3. Piper MA: Special report: genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. BlueCross BlueShield Association. Technology Evaluation Center Volume 10(9) (2004).
4. Meyer UA, Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37, 269-296 (1997).
5. Kirchheiner J. Tsaburidu, M Jabrane W et al.: The 2C9 polymorphism: from enzyme to clinical dose recommendations. Personalized Med. 1, 63-84 (2004).
6. Kirchheiner J, Nickchen K, Bauer M et al.: Pharmacogenetics of antidepressants and the antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry 9, 442-473 (2004).
7. Ruano G, Thompson PD, Windemuth A et al.: Physiogenomic analysis links serum creatinine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6(8), 865-872 (2005).
8. Gordon J, Merante F, Weiss S et al.: Pharmacogenetic P450 screening using the Tag-It™ universal bead-based array platform. In: Pharmacogenomics and Proteomics: Enabling The Practice of Personalized Medicine. Valdes R, Linder M, Wong S (Eds). AACC Press, Washington, DC, USA (In press) (2006).
9. Wilke R, Moore J, Burmester J et al.: Relative impact of CYP3A4 genotype and concomitant medication on the severity of artorvastatin-induced muscle damage. Pharmacogenet. Genomics 15, 415-421 (2005).
10. Droll K, Bruce-Mensah K, Otton SV et al.: Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics 8, 325-333 (1998).
11. McLellan R, Oscarson M, Seidegard J et al.: Frequent occurrences of CYP2D6 gene, duplications in Saudi Arabians. Pharmacogenetics 7, 187-191 (1988).
12. Xie HG, Prasad HC, Kim RB, Stein CM: CYP2C9 allelic variants: ethnic distribution and functional significance. Adv. Drug Deliv. Rev. 54, 1257-1270 (2002).
13. Wilkerson GR: Drug metabolism and variability among patients in drug response. N. Engl. J. Med. 352, 2211-2224 (2005).
14. Andersson T, Flockhart DA, Goldstein DB et al.: Drug metabolizing enzymes: evidence for clinical utility of pharmacogenomic test. Clin. Pharmacol. Ther. 78, 559-581 (2005).
15. deLeon J, Armstrong SC, Cozza K: Clinical guidelines for psychiatrist for the use of pharmacogenetic testing for CYP450 2D6 and 2C19. Psychosomatics 47, 1-12 (2006).
16. Mrazek DA: Clinical implementation of psychiatric pharmacogenomic testing. Personalized Med. 2, 93-95 (2005).
17. Higashi MK, Veenstra DL, Kondo L et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
18. Linder MW, Looney S, Adams JE et al.: Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. J. Thrombosis Thrombolysis 14(3), 227-232 (2002).
19. Womack C: As part of retrofitting. FDA panel votes to relabel warfarin for PGx; Is Dx far behind? Pharmacogenomics Reporter, December 1 (2005).
20. Ruano G: Quo vadis personalized medicine? Personalized Med. 1, 1-7 (2004).